Physician profile
David E Whitt
NPI 1710961438
$3,556.99
in general payments reported to CMS, 2019-2025
14 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $232 · 2022: $371 · 2023: $882 · 2024: $979 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $18.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.19 |
| Education | $18.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,786.83 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Allergan, INC. | $267.04 | 2020-2022 | |
| Lilly USA, LLC | $200.24 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $53.30 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $47.21 | 2023 | |
| Gilead Sciences, INC. | $39.30 | 2023-2024 | |
| Genentech USA, INC. | $35.51 | 2021 | |
| Sunovion Pharmaceuticals INC. | $30.18 | 2021 | |
| Medtronic, INC. | $19.03 | 2024 | Intellis Adaptivestim |
| Lundbeck LLC | $18.76 | 2023 | Rexulti |
| Travere Therapeutics, INC. | $18.30 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $16.77 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $12.36 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Whitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.